Telix Pharmaceuticals Limited (ASX:TLX) entered a new phase in September 2026 with US regulatory approval for Pixclara and a proposed US$1.65 billion combination with ITM Isotope Technologies Munich. Pixclara expands Telix’s commercial diagnostic portfolio beyond prostate cancer, while the ITM transaction would add isotope production capacity, Manufacturing infrastructure and a late-stage therapeutic pipeline. Both developments broaden the business, although the Merger remains subject to Shareholder and regulatory approvals.

Pixclara Adds a New Commercial Product

The US Food and Drug Administration approved Pixclara on 11 September 2026.

Pixclara, or floretyrosine F 18, is a PET imaging agent used to help differentiate recurrent or progressive glioma from treatment-related changes alongside other diagnostic evaluations.

The indication covers adults and paediatric patients aged one month and older.

The approval adds brain cancer imaging to Telix’s existing precision medicine portfolio, which is led by its prostate cancer imaging products Illuccix and Gozellix.

US Commercial Availability Has Begun

Pixclara has moved beyond regulatory approval into commercial use.

Telix announced on 6 October 2026 that the first US patients had received Pixclara in Indianapolis and Cleveland.

The initial doses marked the start of commercial availability in the US and provide the first opportunity for the product to contribute to Telix’s commercial portfolio.

Telix is also progressing the product in Europe under the Pixlumi brand, where its Marketing authorisation application has been accepted for review.

ITM Merger Would Expand Manufacturing Scale

On 21 September 2026, Telix announced an agreement to combine with ITM Isotope Technologies Munich.

The proposed transaction carries upfront consideration of US$1.65 billion on a cash-free, debt-free basis.

After transaction adjustments, ITM shareholders are expected to receive approximately US$1.25 billion in Telix shares.

Additional contingent consideration of up to US$700 million may become payable if specified regulatory approval and commercial sales milestones relating to ITM-11 are achieved.

Ownership of the Enlarged Group Would Change

Following completion, existing Telix shareholders are expected to own approximately 76.3% of the enlarged company.

ITM shareholders would hold approximately 23.7%.

The share-based consideration therefore increases the number of Telix securities on issue while bringing ITM’s isotope manufacturing, distribution network and therapeutic pipeline into the group.

The transaction still requires Telix shareholder approval and other customary regulatory clearances.

ITM Adds Isotope Supply Capabilities

ITM operates a commercial-scale radioisotope manufacturing and distribution network serving more than 65 countries.

Its capabilities include production of isotopes such as lutetium-177, actinium-225 and terbium-161.

This infrastructure would strengthen Telix’s control over parts of its radiopharmaceutical supply chain as its therapeutic pipeline moves toward larger clinical and potential commercial volumes.

ITM generated Revenue of US$273 million in 2025 and operates a profitable isotope production business.

ITM-11 Adds a Late-Stage Therapeutic Asset

The proposed combination would also add ITM-11, a lutetium-177-based treatment being developed for gastroenteropancreatic neuroendocrine tumours.

ITM-11 has completed a Phase 3 study and has another fully enrolled Phase 3 indication-expansion trial under way.

This asset complements Telix’s existing therapeutic pipeline, which includes programs targeting prostate cancer, kidney cancer and glioblastoma.

H1 2026 Revenue Reaches US$477 Million

Telix reported group revenue of US$477 million for H1 2026, up 22% from US$390 million in the prior corresponding period.

Gross profit was US$260 million, with the group gross Margin improving to 55%.

Adjusted EBITDA increased to US$52 million from US$21 million.

Profit after tax was US$38 million compared with a US$2 million loss in H1 2025.

Operating cash flow was US$23 million, while cash stood at US$252 million at 30 June 2026.

R&D Investment Continues to Increase

Research and development expenditure reached US$124 million during the first half, compared with US$82 million a year earlier.

Of this amount, US$68 million was directed toward Telix’s therapeutic pipeline.

The company continues to fund late-stage clinical development while expanding manufacturing capacity and commercial operations.

Telix also completed a refinancing during the half, issuing US$600 million of convertible bonds due in 2031.

FY26 Guidance Remains Above US$1 Billion Including Other Income

Telix expects FY26 revenue and other income to exceed US$1 billion.

Revenue is tracking toward the upper end of the US$950 million to US$970 million guidance range, alongside US$40 million of other income received from a strategic collaboration.

R&D expenditure guidance remains US$230 million to US$270 million for FY26.

BiPASS Adds Another Regulatory Milestone

On 30 September 2026, Telix received FDA Fast Track Designation for its BiPASS prostate cancer imaging program.

BiPASS is evaluating PSMA-PET imaging alongside MRI before prostate biopsy.

Fast Track designation enables more frequent interaction with the FDA and may support an expedited regulatory review process if the program progresses to a new drug application.

Key Risks and Areas to Watch

The ITM transaction remains conditional on shareholder approval, regulatory clearances and other completion requirements.

Integration of a sizeable European isotope and radiopharmaceutical Business would add operational complexity and require Telix to combine manufacturing, clinical-development and commercial activities across a larger organisation.

Existing shareholders would also own a smaller percentage of the enlarged company after ITM shareholders receive Telix equity.

Clinical and Regulatory Risk remains relevant across Telix’s therapeutic pipeline, while isotope manufacturing and distribution require reliable supply chains and specialised infrastructure.